ALSO NOTED: Sciele taps new president and COO; GSK licenses Santarus heartburn drugs

> Sciele Pharma appointed Edward J. Schutter as its new president and chief operating officer. He had been an EVP and chief commercial officer. Report

> Scientists have re-engineered the blockbuster oncology drug Gleevec to eliminate a serious cardiovascular risk, taking a new approach that could offer a significant improvement for "hundreds" of other drugs as well. Report

> GlaxoSmithKline inked a deal to sell Santarus' heartburn drugs in up to 114 countries, in return for an $11.5 million up-front payment plus royalties. Report

> Maxygen has agreed to transfer a portfolio of preclinical dengue antigens to Sanofi Pasteur for use developing a second generation vaccine. Report

> The European Committee for Medicinal Products for Human Use (CHMP) gave its blessing to early use of Bayer's Betaferon against multiple sclerosis; currently the drug is approved for treatment in the disease's more advanced stages. Report

> California-based device maker Sutura and Abbott Laboratories have made a cross-licensing deal to settle patent infringement litigation. Report

And Finally... It's not fat but fitness that predicts longevity in adults over the age of 60. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.